Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story

Papers of special note have been highlighted as: • of interest

References

• 1 US FDA. United States FDA 2004 PDUFA performance report. Performance Reports (2004). www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/ucm2007449.htm.
  Google Scholar
• 2 Ramanathan R, Alvarez N, Su AD et al. Metabolism and excretion of loratadine in male and female mice, rats and monkeys. Xenobiotica 35(2), 155–189 (2005).
  Medline CASGoogle Scholar
• 3 Ramanathan R, Reyderman L, Kulmatycki K et al. Disposition of loratadine in healthy volunteers. Xenobiotica 37(7), 753–769 (2007). • Provides a comprehensive evaluation of loratadine metabolism in laboratory animals.
  Medline CASGoogle Scholar
• 4 Ghosal A, Gupta S, Ramanathan R et al. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab. Lett. 3(3), 162–170 (2009).
  Medline CASGoogle Scholar
• 5 Ghosal A, Yuan Y, Hapangama N et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm. Drug Dispos. 25(6), 243–252 (2004). • Identifies the human UDP-glucuronosyltransferases (UGTs) involved in forming a major metabolite of loratadine/desloratadine.
  Medline CASGoogle Scholar
• 6 Kazmi F, Yerino P, Barbara JE, Parkinson A. Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab. Dispos. 43(9), 1294–1302 (2015).
  Medline CASGoogle Scholar
• 7 Kazmi F, Barbara JE, Yerino P, Parkinson A. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab. Dispos. 43(4), 523–533 (2015).
  Medline CASGoogle Scholar
• 8 Foti RS, Fisher MB. Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding. Drug Metab. Dispos. 32(3), 295–304 (2004).
  Medline CASGoogle Scholar
• 9 Gomez-Lechon MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin. Drug Metab. Toxicol. 4(7), 837–854 (2008).
  Medline CASGoogle Scholar
• 10 Dalvie D, Obach RS, Kang P et al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol. 22(2), 357–368 (2009). • Compares the utility of conventional in vitro hepatic models to predict in vivo relevant metabolites for 27 compounds with well-characterized metabolite profiles.
  Medline CASGoogle Scholar
• 11 Smith CM, Nolan CK, Edwards MA et al. A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. J. Pharm. Sci. 101(10), 3989–4002 (2012). • Investigates in vitro–in vivo correlation of hepatic clearance in long-term hepatic micropatterned co-cultures.
  Medline CASGoogle Scholar
• 12 Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26(1), 120–126 (2008).
  Medline CASGoogle Scholar
• 13 Wang WW, Khetani SR, Krzyzewski S, Duignan DB, Obach RS. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab. Dispos. 38(10), 1900–1905 (2010).
  Medline CASGoogle Scholar
• 14 Chan TS, Yu H, Moore A, Khetani SR, Tweedie D. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab. Dispos. 41(12), 2024–2032 (2013).
  Medline CASGoogle Scholar
• 15 Ballard TE, Wang S, Cox LM et al. Application of a micropatterned cocultured hepatocyte system to predict preclinical and human-specific drug metabolism. Drug Metab. Dispos. 44(2), 172–179 (2016). • Investigates cross-species comparisons of metabolite profiles in long-term hepatic micropatterned co-culture model.
  Medline CASGoogle Scholar
• 16 Hopfgartner G, Tonoli D, Varesio E. High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices. Anal. Bioanal. Chem. 402(8), 2587–2596 (2012).
  Medline CASGoogle Scholar
• 17 Andrews GL, Simons BL, Young JB, Hawkridge AM, Muddiman DC. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Anal. Chem. 83(13), 5442–5446 (2011).
  Medline CASGoogle Scholar
• 18 Ramanathan R, Ramagiri S, Aratyn-Schaus Y et al. Advances in HRMS and in vitro systems provide an option to detect and characterize human disproportionate metabolites of loratadine/desloratadine Presented at: The 63rd ASMS Conference on Mass Spectrometry. MO, USA, 31 May–4 June 2015.
  Google Scholar
• 19 Sidoli S, Lin S, Xiong L et al. Sequential Window Acquisition of all Theoretical Mass Spectra (SWATH) analysis for characterization and quantification of histone post-translational modifications. Mol. Cell. Proteomics 14(9), 2420–2428 (2015).
  Medline CASGoogle Scholar
• 20 Wohlfarth A, Castaneto MS, Zhu M et al. Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J. 17(3), 660–677 (2015).
  Medline CASGoogle Scholar
• 21 Zelesky V, Schneider R, Janiszewski J, Zamora I, Ferguson J, Troutman M. Software automation tools for increased throughput metabolic soft-spot identification in early drug discovery. Bioanalysis 5(10), 1165–1179 (2013). • Investigates software programs for metabolite profiling and identification.
  CASGoogle Scholar
• 22 Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol. 51(2), 165–172 (1996).
  Medline CASGoogle Scholar
• 23 US FDA. FDA (2010) Guidance for Industry M3(R2). Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (2010). • The US FDA guidance document on bioanalysis.
  Google Scholar
• 24 Gao H, Obach RS. A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments (metabolites in safety testing). II. Application to unstable metabolites. Drug Metab. Dispos. 40(7), 1290–1296 (2012).
  Medline CASGoogle Scholar
• 25 Gao H, Obach RS. Addressing MIST (metabolites in safety testing): bioanalytical approaches to address metabolite exposures in humans and animals. Curr. Drug Metab. 12(6), 578–586 (2011).
  Medline CASGoogle Scholar
• 26 Ramanathan R, Josephs JL, Jemal M, Arnold M, Humphreys WG. Novel MS solutions inspired by MIST. Bioanalysis 2(7), 1291–1313 (2010). • A review of the MIST guidance and associated LC–MS techniques.
  CASGoogle Scholar
• 27 Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR. Microengineered liver tissues for drug testing. J. Lab. Autom. 20(3), 216–250 (2015).
  Medline CASGoogle Scholar
• 28 Davidson MD, Ware BR, Khetani SR. Stem cell-derived liver cells for drug testing and disease modeling. Discov. Med. 19(106), 349–358 (2015).
  MedlineGoogle Scholar
• 29 Ware BR, Berger DR, Khetani SR. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol. Sci. 145(2), 252–262 (2015).
  Medline CASGoogle Scholar
• 30 Nguyen TV, Ukairo O, Khetani SR et al. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab. Dispos. 43(5), 774–785 (2015).
  Medline CASGoogle Scholar